RT Journal Article
SR Electronic
T1 Metabolite-based dietary supplementation in human type 1 diabetes is associated with microbiota and immune modulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.15.21263059
DO 10.1101/2021.09.15.21263059
A1 Kirstine J. Bell
A1 Sonia Saad
A1 Bree J. Tillett
A1 Helen M. McGuire
A1 Sara Bordbar
A1 Yu Anne Yap
A1 Long T. Nguyen
A1 Marc R. Wilkins
A1 Susan Corley
A1 Shannon Brodie
A1 Sussan Duong
A1 Courtney J. Wright
A1 Stephen Twigg
A1 Barbara Fazekas de St Groth
A1 Leonard C. Harrison
A1 Charles R. Mackay
A1 Esteban N. Gurzov
A1 Emma E. Hamilton-Williams
A1 Eliana Mariño
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263059.abstract
AB Background Short-chain fatty acids (SCFAs) produced by the gut microbiota have beneficial anti-inflammatory and gut homeostasis effects and prevent type 1 diabetes (T1D) in mice. Reduced SCFA production indicates a loss of beneficial bacteria, commonly associated with chronic autoimmune and inflammatory diseases, including T1D and type 2 diabetes. Here we addressed whether a metabolite-based dietary supplement has an impact on humans with T1D. We conducted a single-arm pilot-and-feasibility trial with high-amylose maize resistant starch modified with acetate and butyrate (HAMSAB) to assess safety, while monitoring changes in the microbiota in alignment with modulation of the immune system status.Results HAMSAB supplement was administered for six weeks with follow-up at 12 weeks in adults with long-standing T1D. Increased concentrations of SCFA acetate, propionate, and butyrate in stools and plasma were in concert with a shift in the composition and function of the gut microbiota. While glucose control and insulin requirements did not change, subjects with the highest SCFA concentrations exhibited the best glycemic control. Bifidobacterium longum, Bifidobacterium adolescentis, and vitamin B7 production correlated with lower HbA1c and basal insulin requirements. Circulating B and T cells developed a more regulatory phenotype post-intervention.Conclusion Changes in gut microbiota composition, function, and immune profile following six weeks of HAMSAB supplementation were associated with increased SCFAs in stools and plasma. The persistence of these effects suggests that targeting dietary SCFAs may be a mechanism to alter immune profiles, promote immune tolerance and improve glycemic control for the treatment of T1D.Trial registration ACTRN12618001391268. Registered 20 August 2018, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375792Competing Interest StatementThe authors have declared no competing interest.Clinical TrialACTRN12618001391268Funding StatementThis work was supported by the JDRF Australian Type 1 Diabetes Clinical Research Network (2‐SRA‐2019‐703‐M‐B) a special initiative of the Australian Research Council (ARC). Monash University, National Health & Medical Research Council, the International Society for the Advancement of Cytometry (ISAC) Marylou Ingram Scholars program. JDRF International (3-SRA-2019-730-S-B and 5-CDA-2019-758-A-N), the Children Hospital Foundation (50316) and Research Associate of the Fonds National de la Recherche Scientifique (FNRS)-Belgium. Part of this research was carried out at Monash University, Melbourne and the Translational Research Institute, Woolloongabba, Queensland, Australia. The Translational Research Institute is supported by a grant from the Australian Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the Sydney Local Health District Human Research Ethics Committee (HREC) (HREC/18/RPAH/241) and Monash University HREC. Use of the intervention for clinical investigation has been approved by Therapeutic Goods Administration (TGA) (CT-2020-CTN00691-1 v1). All patients provided written informed consent. The trial was registered with Australia New Zealand Clinical Trials Registry (ACTRN12618001391268).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMetagenomic data is deposited in the European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena and RNA-seq data is uploaded in the Gene Expression Omnibus (GEO) database.